Elastin-like Polypeptide Adhesives for Wet Tissue Bonding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FDA-approved adhesives for biomedical applications face challenges such as toxicity, limited adhesion in wet environments, and potential for blood-borne pathogen transmission, and they require a dry surface for optimal bonding, which restricts their use in wet conditions like wound closure.
Innovation Solution
Development of elastin-like polypeptides with specific repeating sequences that can form coacervates and convert tyrosine to dihydroxyphenylalanine, enabling strong adhesion in wet environments without the need for a dry surface, and are cytocompatible for biomedical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If current FDA-approved adhesives are used, then adhesion strength can be achieved in dry conditions, but adhesion performance deteriorates in wet environments
Solution Approach 1:
The invention modifies the chemical composition of the adhesive by incorporating specific amino acid sequences (particularly those containing tyrosine, DOPA, or TOPA residues) that change the adhesive's interaction with water. This compositional parameter change enables the adhesive to maintain strong bonding in wet conditions while preserving dry adhesion performance.
Solution Approach 2:
The invention creates composite adhesive materials that combine synthetic or natural polymer backbones with bioinspired adhesive domains containing aromatic amino acids. This composite structure integrates the benefits of both synthetic adhesives (strength, stability) and natural adhesives (wet adhesion capability), resolving the contradiction between dry and wet environment performance.
2Strength
If cyanoacrylate-based adhesives are used, then strong adhesion is achieved, but toxic degradation products are generated
Solution Approach 1:
The invention employs biodegradable peptide-based adhesives that break down into non-toxic amino acid components after serving their bonding function. This approach replaces persistent toxic adhesives with temporary, environmentally benign alternatives that maintain adhesion strength during use but eliminate long-term toxicity concerns.
Solution Approach 2:
The invention converts the typical weakness of peptides (low mechanical strength) into a benefit by designing them to degrade into non-toxic amino acids, thereby transforming potential harm (weakness) into a beneficial safety feature. The adhesive provides sufficient strength during use but safely decomposes afterward, eliminating toxic residue.
3Strength
If fibrin sealants are used, then adhesion is achieved, but risk of blood-borne pathogen transmission exists
Solution Approach 1:
The invention employs synthetic or recombinant peptide adhesives that are produced in controlled environments without exposure to blood-borne pathogens. These single-use, sterile adhesives eliminate the risk of pathogen transmission associated with human-derived fibrin sealants while maintaining effective adhesion strength.
Solution Approach 2:
The invention introduces recombinant DNA technology as an intermediary to produce human-like adhesive proteins in safe, controlled cellular systems. This intermediary process creates adhesives with the desired biological functionality but without the contamination risks of direct human blood products.
4Ease of operation
If PEG adhesives are used, then sealing capability is achieved, but inflammatory response occurs due to swelling
Solution Approach 1:
The invention modifies the hydrophilicity and crosslinking density parameters of the adhesive material to control water uptake and swelling behavior. By adjusting these parameters, the adhesive achieves effective sealing capability while limiting excessive swelling that triggers inflammatory responses.
Solution Approach 2:
The invention creates composite hydrogel adhesives that combine PEG or similar hydrophilic polymers with crosslinking agents and bioactive peptides. This composite structure provides sealing capability through controlled swelling while the crosslinked network limits excessive expansion, reducing inflammatory response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The elastin-like polypeptides demonstrate enhanced adhesion strength in both dry and wet conditions, surpassing commercial adhesives like Tisseel, and show high cytocompatibility, making them suitable for biomedical applications without the drawbacks of existing adhesives.
Implementation Method 1
An alternative method for underwater application uses the phenomenon of coacervation, a form of aqueous liquid-liquid phase separation that is implicated in the adhesion mechanism of sandcastle worms, caddisfly larvae, and mussels.
Implementation Method 2
Development of elastin-like polypeptides with specific repeating sequences that can form coacervates and convert tyrosine to dihydroxyphenylalanine
Data Source
AI summary
Protein-based adhesives. In one embodiment of the present disclosure, an elastin-like polypeptide has a sequence LDGTL-(PGX1GVPGKGVPGX2GVPGX1GVPGX3GVPGX2GV)n-PVADRGMRLE, wherein each X1 is selected from the group consisting of tyrosine (Y), dihydroxyphenylalanine (DOPA), and 3,4,5-trihydroxyphenylalanine (TOPA), wherein each X2 is selected from the group consisting of valine (V), Y, DOPA, and TOPA, wherein each X3 is selected from the group consisting of glutamic acid (E) and lysine (K), and wherein n is at or between 6 and 10 or higher or lower.